Aspen Pharmacare Holdings
About
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
Industry Trade Show
Booth #27, Level 2
19-22 May, 2025
Industry Trade Show
Attending
10-12 June, 2025
CONTACT DETAILS
Digital content 
NEWS #PharmaBuzz
05 Mar 2025
// REUTERS
04 Dec 2023
// Zoey Becker FIERCE PHARMA
19 Sep 2023
// Fraiser Kansteiner FIERCE PHARMA
30 Aug 2023
// PRESS RELEASE
30 Aug 2023
// PRESS RELEASE
18 Jul 2023
// PRESS RELEASE
Drugs in Development
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Aspen Announces Local Availability of Lilly’s Mounjaro
Details : Mounjaro (tirzepatide) injection is an obesity treatment targeting GIP and GLP-1 hormone receptors. Currently it is indicated for the treatment of type 2 diabetes mellitus and obesity.
Product Name : Mounjaro
Product Type : Peptide
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Gates Foundation
Deal Size : $30.0 million
Deal Type : Funding
Details : PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.
Product Name : Pneumosil
Product Type : Vaccine
Upfront Cash : Undisclosed
December 12, 2022
Lead Product(s) : 10-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Serum Institute of India
Deal Size : Undisclosed
Deal Type : Collaboration
Details : PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countrie...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
August 31, 2022
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Australia Registers First Eye Drops to Slow Short-sightedness Progress in Children
Details : EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.
Product Name : Eikance
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2022
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Debiopharm
Deal Size : Undisclosed
Deal Type : Partnership
Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar® In South Africa
Details : Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer pat...
Product Name : Trelstar
Product Type : Hormone
Upfront Cash : Undisclosed
January 02, 2022
Lead Product(s) : Ad26.COV2.S
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Johnson & Johnson
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage
Details : The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.
Product Name : JNJ-78436735
Product Type : Vaccine
Upfront Cash : Undisclosed
November 30, 2021
Lead Product(s) : Esomeprazole Magnesium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Acino Pharma
Deal Size : $119.4 million
Deal Type : Acquisition
Acino Acquires Selected Aspen Brands in South Africa
Details : The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.
Product Name : Trustan
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 22, 2021
Lead Product(s) : Conjugated Estrogens
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Avion Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals
Details : Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy d...
Product Name : Cenestin
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 11, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Agreement
Aspen Concludes Agreement to Manufacture and Make Available Aspenovax Throughout Africa
Details : The agreement aims to manufacture and make available Aspenovax, an Aspen-branded COVID-19 vaccine, across Africa.
Product Name : Aspenovax
Product Type : Vaccine
Upfront Cash : Undisclosed
September 08, 2020
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Viatris
Deal Size : $757.2 million
Deal Type : Acquisition
Divestment of Aspen’s European Thrombosis Business to Mylan and Withdrawal of Cautionary
Details : Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
Product Name : Arixtra
Product Type : Other Small Molecule
Upfront Cash : $310.4 million
August 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : ORGARAN
Dosage Strength : 750 UNITS/0.6ML
Approval Date : 1996-12-24
Application Number : 20430
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
DESOGESTREL; ETHINYL ESTRADIOL
Dosage Form : TABLET; ORAL-28
Proprietary Name : CYCLESSA
Dosage Strength : 0.1MG,0.125MG,0.15MG;0.0...
Approval Date : 2000-12-20
Application Number : 21090
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Dosage Form : ELIXIR; ORAL
Proprietary Name : HEXADROL
Dosage Strength : 0.5MG/5ML
Approval Date : 1982-01-01
Application Number : 12674
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : HEXADROL
Dosage Strength : 0.5MG
Approval Date : 1982-01-01
Application Number : 12675
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : HEXADROL
Dosage Strength : 0.75MG
Approval Date : 1982-01-01
Application Number : 12675
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : HEXADROL
Dosage Strength : 1.5MG
Approval Date : 1982-01-01
Application Number : 12675
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : HEXADROL
Dosage Strength : 4MG
Approval Date : 1982-01-01
Application Number : 12675
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
DEXAMETHASONE SODIUM PHOSPHATE
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : HEXADROL
Dosage Strength : EQ 4MG PHOSPHATE/ML **Fe...
Approval Date : 1982-01-01
Application Number : 14694
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
DEXAMETHASONE SODIUM PHOSPHATE
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : HEXADROL
Dosage Strength : EQ 10MG PHOSPHATE/ML **F...
Approval Date : 1982-01-01
Application Number : 14694
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
DEXAMETHASONE SODIUM PHOSPHATE
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : HEXADROL
Dosage Strength : EQ 20MG PHOSPHATE/ML
Approval Date : 1982-01-01
Application Number : 14694
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
